Capsules

Updated on February 05, 2018

Working on an action plan to address challenges in developing medicines for children   -  Getty Images/iStockphoto

 

EU WORKSHOP

Medicines for kids

The European Medicines Agency (EMA) is inviting expressions of interest in a workshop organised together with the European Commission on March 20 to discuss potential improvements to the implementation of the European Union’s regulatory framework specific for paediatric medicines, the Paediatric Regulation. The workshop is a crucial step for the development of an action plan to address challenges to medicine development for children in Europe.

REGULATORY ACTION

Boxed warning on liver drug

The US Food and Drug Administration is warning that the liver disease medicine Ocaliva (obeticholic acid) has been incorrectly dosed daily instead of weekly in patients with moderate to severe primary biliary cholangitis (PBC), a rare chronic liver disease, increasing the risk of serious liver injury. “We are clarifying the recommendations for screening, dosing, monitoring, and managing PBC patients with moderate to severe liver disease taking Ocaliva. We are adding a new Boxed Warning to highlight this information in the prescribing information of the drug label,” the agency said.

MUTATION ALERT

Multidrug-resistant malaria

The current spread of multidrug-resistant malaria in Southeast Asia is likely to be the result of two mutations combining in 2008, according to a retrospective genetic study published in The Lancet Infectious Diseases journal. The study shows how the multidrug-resistant parasite gained increased biological fitness, spreading rapidly through the region unnoticed for 5 years until 2013.

Combating multidrug-resistant malaria   -  Getty Images/iStockphoto

 

Published on February 05, 2018

MORE FROM BUSINESSLINE


 Getting recommendations just for you...
  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.